弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)是血液系统疾病最常见的恶性增殖性疾病,具有较大的异质性,是免疫刺激、免疫抑制、患者遗传易感性综合作用的结果。研究表明,外周血炎症指标及其相关炎症复合指数对早期识别高危DLBCL患者和提高疗效及改善预后方面显示出巨大的潜力,可能成为评估DLBCL诊断及预后的有效指标。本文就中性粒细胞、淋巴细胞、血小板、β2-MG、D-二聚体、C-反应蛋白等常见的外周血炎症指标及相关炎症复合指数与弥漫大B细胞淋巴细胞瘤预后关系的研究进展作一综述。旨在探讨DLBCL患者外周血中影响预后的相关检测指标,以求更有效地预测预后,指导临床治疗。 Diffuse large B-cell lymphoma (DLBCL) is the most common proliferative disease of hematology and is the result of a combination of immunostimulation, immunosuppression, and genetic predisposi-tion of patients. Studies have shown that peripheral blood inflammatory indicators and related in-flammatory complex indexes show great potential in early identification of high-risk DLBCL patients and in improving efficacy and prognosis, and may become effective indicators to evaluate the diag-nosis and prognosis of DLBCL. In this paper, we review the research progress of the relationship between common inflammatory indexes in peripheral blood, such as neutrophils, lymphocytes, platelets, β2-MG, D-dimer, C-reactive protein and the prognosis of diffuse large B-cell lymphoma. The objective is to explore the related detection indicators in peripheral blood of DLBCL patients that affect prognosis, so as to predict prognosis more effectively and guide clinical treatment.
弥漫性大B细胞淋巴瘤,中性粒细胞与淋巴细胞比值,系统免疫炎症指数,β2-微球蛋白,D-二聚体, C反应蛋白 , Diffuse Large B-Cell Lymphoma
Neutrophil to Lymphocyte Ratio (NLR)
Systemic Immune Inflammatory Index (SII)
Beta-2-Microglobulin
D-Dimer
C-Reactive Protein
摘要
弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma, DLBCL)是血液系统疾病最常见的恶性增殖性疾病,具有较大的异质性,是免疫刺激、免疫抑制、患者遗传易感性综合作用的结果。研究表明,外周血炎症指标及其相关炎症复合指数对早期识别高危DLBCL患者和提高疗效及改善预后方面显示出巨大的潜力,可能成为评估DLBCL诊断及预后的有效指标。本文就中性粒细胞、淋巴细胞、血小板、β2-MG、D-二聚体、C-反应蛋白等常见的外周血炎症指标及相关炎症复合指数与弥漫大B细胞淋巴细胞瘤预后关系的研究进展作一综述。旨在探讨DLBCL患者外周血中影响预后的相关检测指标,以求更有效地预测预后,指导临床治疗。
Diffuse large B-cell lymphoma (DLBCL) is the most common proliferative disease of hematology and is the result of a combination of immunostimulation, immunosuppression, and genetic predisposition of patients. Studies have shown that peripheral blood inflammatory indicators and related inflammatory complex indexes show great potential in early identification of high-risk DLBCL patients and in improving efficacy and prognosis, and may become effective indicators to evaluate the diagnosis and prognosis of DLBCL. In this paper, we review the research progress of the relationship between common inflammatory indexes in peripheral blood, such as neutrophils, lymphocytes, platelets, β2-MG, D-dimer, C-reactive protein and the prognosis of diffuse large B-cell lymphoma. The objective is to explore the related detection indicators in peripheral blood of DLBCL patients that affect prognosis, so as to predict prognosis more effectively and guide clinical treatment.
Keywords:Diffuse Large B-Cell Lymphoma, Neutrophil to Lymphocyte Ratio (NLR), Systemic Immune Inflammatory Index (SII), Beta-2-Microglobulin, D-Dimer, C-Reactive Protein
文海霞,罗 伟. 外周血检测指标在弥漫大B细胞淋巴瘤预后评估中应用价值的研究进展Research Progress on the Application Value of Peripheral Blood Detection Indicators in Prognostic Evaluation of Diffuse Large B-Cell Lymphoma[J]. 临床医学进展, 2023, 13(06): 10560-10567. https://doi.org/10.12677/ACM.2023.1361477
参考文献References
Duan, S., Zhang, Y. and Xu, S. (2022) Contrast-Enhanced Ultrasound Parameters and D-Dimer: New Prognostic Pa-rameters for Diffuse Large B-Cell Lymphoma. Cancer Management and Research, 14, 2535-2544. https://doi.org/10.2147/CMAR.S326173
Li, S., Young, K.H. and Medeiros, L.J. (2018) Diffuse Large B-Cell Lymphoma. Pathology, 50, 74-87. https://doi.org/10.1016/j.pathol.2017.09.006
杨铭, 张清媛. 外周血检测指标在弥漫大B细胞淋巴瘤预后评估中应用价值的研究进展[J]. 癌症进展, 2020, 18(7): 657-660.
Geng, Y.D., Chen, Y.R. and Jin, J. (2019) Prognostic Value of D-Dimer in Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Study. Current Medical Science, 39, 222-227. https://doi.org/10.1007/s11596-019-2023-5
Dehghani, M., Kalani, M. and Golmoghad-dam, H. (2020) Aberrant Peripheral Blood CD4(+) CD25(+) FOXP3(+) Regulatory T Cells/T Helper-17 Number Is Associated with the Outcome of Patients with Lymphoma. Cancer Immunology, Immunotherapy, 69, 1917-1928. https://doi.org/10.1007/s00262-020-02591-y
熊婕妤, 罗明青. NLR和PLR对弥漫大B细胞淋巴瘤患者预后的影响[J]. 重庆医学, 2020, 49(21): 3520-3525.
Zhao, P., Zang, L. and Zhang, X. (2018) Novel Prognostic Scoring System for Diffuse Large B-Cell Lymphoma. Oncology Letters, 15, 5325-5332. https://doi.org/10.3892/ol.2018.7966
Chen, Y., Zhang, Z. and Fang, Q. (2019) Prognostic Impact of Plate-let-to-Lymphocyte Ratio on Diffuse Large B-Cell Lymphoma: A Meta-Analysis. Cancer Cell International, 19, Article No. 245. https://doi.org/10.1186/s12935-019-0962-3
Yang, J., Liao, D. and Chen, C. (2013) Humor-Associated Mac-rophages Regulate Murine Breast Cancer Stem Cells through a Novel Paracrine EGFR/Stat3/Sox-2 Signaling Pathway. Stem Cells, 31, 248-258. https://doi.org/10.1002/stem.1281
Hong, J.Y., Ryu, K.J. and Lee, J.Y. (2017) Serum Level of CXCL10 Is Associated with Inflammatory Prognostic Biomarkers in Patients with Diffuse Large B-Cell Lymphoma. Hematological Oncology, 35, 480-486. https://doi.org/10.1002/hon.2374
Wu, J., Zhu, H. and Zhang, Q. (2022) Nomogram Based on the Systemic Immune-Inflammation Index for Predicting the Prognosis of Diffuse Large B-Cell Lymphoma. Asia-Pacific Journal of Clinical Oncology, 19, e138-e148. https://doi.org/10.1111/ajco.13806
Wang, S., Ma, Y. and Sun, L. (2018) Prognostic Significance of Pretreat-ment Neutrophil/Lymphocyte Ratio and Platelet/Lymphocyte Ratio in Patients with Diffuse Large B-Cell Lymphoma. BioMed Research International, 2018, Article ID: 9651254. https://doi.org/10.1155/2018/9651254
Menter, D.G., Tucker, S.C. and Kopetz, S. (2014) Platelets and Cancer: A Casual or Causal Relationship: Revisited. Cancer and Metastasis Reviews, 33, 231-269. https://doi.org/10.1007/s10555-014-9498-0
Wang, J., Zhou, X. and Liu, Y. (2017) Prognostic Significance of Neutrophil-to-Lymphocyte Ratio in Diffuse Large B-Cell Lymphoma: A Me-ta-Analysis. PLOS ONE, 12, e0176008. https://doi.org/10.1371/journal.pone.0176008
李敬东, 韩效林, 杨翠. DLBCL患者CHOP或R-CHOP化疗前后中性粒细/淋巴细胞比值的变化及其对生存的影响[J]. 中国实验血液学杂志, 2018, 26(1): 182-186.
杨梦珠. 弥漫大B细胞淋巴瘤患者外周血NLR、PLR以及LDH的水平及其临床意义[D]: [硕士学位论文]. 新乡: 新乡医学院, 2021.
张林艳. 中性粒细胞/淋巴细胞比值对弥漫大B细胞淋巴瘤患者的预后价值[D]: [硕士学位论文]. 太原: 山西医科大学, 2019.
刘佳为. 中性粒细胞-淋巴细胞比值和血小板-淋巴细胞比值对弥漫大B细胞淋巴瘤的预后价值[D]: [硕士学位论文]. 济南: 山东大学, 2020.
朱明, 李延莉, 王芝涛. 弥漫大B细胞淋巴瘤患者中性粒细胞/淋巴细胞比值与疗效及预后的关系[J]. 白血病∙淋巴瘤, 2015, 24(8): 460-463.
Choi, M., Lee, J.O. and Jung, J. (2019) Prognostic Value of Platelet Count in Patients with Peripheral T Cell Lymphoma. Acta Haematologica, 141, 176-186. https://doi.org/10.1159/000495337
Wu, X.B., Hou, S.L. and Liu, H. (2021) Systemic Immune Inflammation Index, Ratio of Lymphocytes to Monocytes, Lactate Dehydrogenase and Prognosis of Diffuse Large B-Cell Lymphoma Patients. World Journal of Clinical Case Reports, 9, 9825-9834. https://doi.org/10.12998/wjcc.v9.i32.9825
Wang, Z., Zhang, J. and Luo, S. (2021) Prognostic Significance of Systemic Immune-Inflammation Index in Patients with Diffuse Large B-Cell Lymphoma. Frontiers in Oncology, 11, Ar-ticle ID: 655259. https://doi.org/10.3389/fonc.2021.655259
Chen, L., Kong, X. and Wang, Z. (2020) Pre-Treatment Systemic Immune-Inflammation Index Is a Useful Prognostic Indicator in Patients with Breast Cancer Undergoing Neoadjuvant Chemotherapy. Journal of Cellular and Molecular Medicine, 24, 2993-3021. https://doi.org/10.1111/jcmm.14934
Tong, Y.S., Tan, J. and Zhou, X.L. (2017) Systemic Im-mune-Inflammation Index Predicting Chemoradiation Resistance and Poor Outcome in Patients with Stage III Non-Small Cell Lung Cancer. Journal of Translational Medicine, 15, Article No. 221. https://doi.org/10.1186/s12967-017-1326-1
陈娟, 石志, 娄慧娟. 系统免疫-炎症指数对初诊多发性骨髓瘤患者预后的评估价值[J]. 临床血液学杂志, 2022, 35(3): 180-186.
郑永青, 孙明东, 王瑞芳. 血清β_2-MG联合LDH在弥漫性大B细胞淋巴瘤预后判断中的意义[J]. 疑难病杂志, 2022, 21(6): 582-587.
张青, 李承彬, 邓明凤. 弥漫大B细胞性淋巴瘤患者Ki-67、β2-MG、CRP、ESR的水平变化及意义[J]. 微循环学杂志, 2021, 31(2): 57-61.
刘文涛. β2-MG、IL-17及VEGF水平表达对多发性骨髓瘤患者疾病进展及预后的影响[J]. 新疆医学, 2022, 52(6): 632-634.
于明雪, 刘加军. 高β2微球蛋白对弥漫大B细胞淋巴瘤的临床意义[J]. 蚌埠医学院学报, 2020, 45(8): 1040-1043.
卢丹, 胡艳, 袁韵. 弥漫大B细胞淋巴瘤患者血清β_2-MG水平与预后的关系[J]. 标记免疫分析与临床, 2020, 27(12): 2059-2062.
熊丽丽. 血清LDH、β_2-MG、CA125水平变化与弥漫大B细胞淋巴瘤患者临床分期、疾病转归的关联性探究[J]. 医学理论与实践, 2022, 35(10): 1748-1750.
黄天骄, 周虹, 刘松涛. 弥漫大B细胞淋巴瘤患者血清中乳酸脱氢酶、β2微球蛋白及尿酸临床意义[J]. 临床血液学杂志, 2021, 34(6): 412-414.
李青芬, 张启科, 魏小芳. 多发性骨髓瘤患者凝血指标水平及预后意义[J]. 中国实验血液学杂志, 2021, 29(3): 791-796.
卜广瑞, 张艳敏, 徐李红. 多发性骨髓瘤患者的凝血指标变化及临床意义[J]. 血栓与止血学, 2022, 28(3): 450-451+453.
Liu, B., Li, B. and Zhou, P. (2018) Prognostic Value of Pretreatment Plasma D-Dimer Levels in Patients with Diffuse Large B Cell Lymphoma (DLBCL). Clinica Chimica Acta, 482, 191-198. https://doi.org/10.1016/j.cca.2018.04.013
Huang, H., Fan, L. and Fu, D. (2021) High Pretreatment Plasma D-Dimer Levels Predict Poor Survival in Patients with Diffuse Large B-Cell Lymphoma in the Real World. Translational Cancer Research, 10, 1723-1731. https://doi.org/10.21037/tcr-20-2908
刘文洁, 李兰竹, 孙倩. D-二聚体/纤维蛋白原比值在急性髓系白血病患者中的临床意义分析[J]. 临床肿瘤学杂志, 2021, 26(12): 1079-1084.
叶韬, 宋红蕾, 胡岳棣. 血浆D-二聚体评估非霍奇金淋巴瘤疗效的价值[J]. 现代肿瘤医学, 2016, 24(17): 2765-2768.
Gradel, K.O., Larsen, T.S. and Frederiksen, H. (2022) Impact of C-Reactive Protein and Albumin Levels on Short, Medium, and Long-Term Mor-tality in Patients with Diffuse Large B-Cell Lymphoma. Annals of Medicine, 54, 713-722. https://doi.org/10.1080/07853890.2022.2046287
Qin, W., Yuan, Q. and Wu, J. (2019) Prognostic Value of Pre-Therapy C-Reactive Protein Level in Diffuse Large B-Cell Lymphoma: A Meta-Analysis. Leukemia & Lymphoma, 60, 358-366. https://doi.org/10.1080/10428194.2018.1482540
黄琴, 王增胜, 李燕. 血清C反应蛋白在弥漫大B细胞淋巴瘤预后中的意义[J]. 肿瘤研究与临床, 2016, 28(4): 244-247.
潘必慧, 孔祎琳, 王莉. C反应蛋白/白蛋白比值在弥漫大B细胞淋巴瘤患者中的预后价值[J]. 南京医科大学学报(自然科学版), 2020, 40(2): 228-233.
何昕, 高海燕, 姜永芳. 血清C-反应蛋白对弥漫大B淋巴瘤患者预后评估及相关性分析[J]. 标记免疫分析与临床, 2017, 24(8): 856-858.
何婧, 施文瑜. 血清载脂蛋白C1、C反应蛋白及白介素6水平在弥漫大B细胞淋巴瘤诊断中的预测价值[J]. 交通医学, 2022, 36(1): 1-9.